In regard to Avastin, it is in a phase II trial: Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma, NCT00513786. The purpose of this study is to test the effectiveness, safety, and tolerability of the drug combination carboplatin, paclitaxel, and bevacizumab(Avastin) in patients with advanced stage endometrial carcinoma. This is a phase II,open label,single center study. There is also GOG 0209 - A Randomized Phase III trial of Doxorubicin/Cisplatin/Paclitaxel/G-CSF Vs. Carboplatin/Paclitaxel in patients with Stage III & IV or recurrent endometrial cancer. There was a very smal pashe II trial in 11 patients that concluded: "Bevacizumab was well-tolerated and displayed promising anti-neoplastic activity in patients with endometrial cancer and uterine leiomyosarcoma."
WRIGHT Jason D. et al, Bevacizumab therapy in patients with recurrent uterine neoplasms Anticancer research ISSN 0250-7005 2007, vol. 27, no5B, pp. 3525-3528
Michael Montejo et al, Current challenges in clinical management of endometrial cancer Advanced Drug Delivery Reviews Volume 61, Issue 10, 10 August 2009, Pages 883-889